MOLE.L Новости Форекс
Moleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AML
Pharmaceutical company Moleculin Biotech, Inc. (MBRX) announced Thursday that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of Acute Myeloid Leukemia (AML).
RTTNews
|
900 дней спустя
